PDCD1 and colorectal carcinoma: It accentuated the importance of mismatch repair status as a reliable predictor for the clinical benefit of immune checkpoint blockade therapies in patients [30], while Table 2 summarizes the clinical trials in which immune checkpoints against PD-1/PD-L1 were combined with different lines of conventional therapies in MSS/pMMR CRC patients.